PDCD1 and cancer: Clinically, ICIs such as anti-CTLA-4, anti-PD-1, PD-L1, and the novel immune checkpoint inhibitor LAG-3 have demonstrated efficacy across various cancer types, resulting in improved patient outcomes [51,52].